Video
What’s next for sacral neuromodulation in OAB patients with Parkinson’s disease?
Author(s):
“I think the take home message is not to take sacral neuromodulation off the table,” says Sarah Martin, DO.
Video Player is loading.
In this video, Sarah Martin, DO, discusses the take-home message from the recent Neurourology & Urodynamics study, “Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review,” for which she served as first author. Martin is an FPMRS fellow at Glickman Urological & Kidney Institute at Cleveland Clinic.
Related Videos
Anna Myers, CNP, discusses her approach to preventing UTIs
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Ian Metzler, MD, on the increasing prevalence of kidney stones in women
How pre-URS tamsulosin use in pediatric patients may reduce repeat procedures
An expert discusses patient counseling in wake of FDA’s labeling changes for testosterone
Ekene Enemchukwu, MD, on vaginal estrogen for genitourinary syndrome of menopause
Expert discusses innovations in single-use ureteroscopes for stones
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Related Content
